RUA RUA Life Sciences plc
RUA Life Sciences plc, together with its subsidiaries, develops medical devices in Europe, North America, the Middle East, the Asia Pacific, and Africa. It operates through four segments: Biomaterials, Contract Manufacture, Vascular, and Structural Heart. The company acts as the depository of intellectual property and licensing rights to various biostable and implantable polymers, including Elast-Eon and ECSil; and provides sub-contract manufacturing, assembly, packing, and services of medical device, as well as implantable fabric. It also engages in the development and commercialization of bore polymer sealed grafts and soft tissue patches; and development of tri-leaflet polymeric heart valves. The company was formerly known as AorTech International plc and changed its name to RUA Life Sciences plc in June 2020. RUA Life Sciences plc was incorporated in 1996 and is headquartered in Irvine, the United Kingdom.…
Industry Peers
Medical DevicesKey Statistics
About RUA Life Sciences (LON: RUA)
›
RUA Life Sciences (LON: RUA) is listed on the London Stock Exchange, where its shares trade in pence sterling (GBp). It belongs to the Medical Devices industry, part of the Healthcare sector, and reports about 59 employees.
The shares were at 19.50 GBp on 19 November 2026, up 56.0% over 52 weeks. Its 52-week range is 11.50 GBp to 31.00 GBp: the price is 37.1% below the high and 69.6% above the low.
Its market capitalisation is 12.10M GBP.
RUA Life Sciences reports return on equity of -20.1%, an operating margin of 2.9% and revenue up 6.1% year over year.
It holds more cash than debt, a net cash position of 1.71M GBP. Its Piotroski F-score is 4 out of 9, an average reading of its financial health. One analyst covers the stock, with an average rating of Strong Buy; their mean price target of 50.00 GBp is 156.4% above the current price.